Clinicn Investigator, Assc Prf Cancer Center, Mass General Research Institute

Associate Professor of Medicine Harvard Medical School

Assistant In Medicine Medicine-Hematology/Oncology, Massachusetts General Hospital

MD UC San Francisco School of Medicine 2005

biomarkers of ovarian cancer; exosome analysis; extracellular vesicles; holography; magnetic resonance spectroscopy; magnetite nanoparticles; miniaturization; molecular diagnostic techniques; nanomedicine; nanoparticles; nanotechnology; neoplastic cells circulating; neurosecretory systems; ovarian cancer; ovarian neoplasms; uteroglobin

My research endeavors seek to bridge advances in novel technologies and therapeutics with current clinical oncology needs.

Prior formal intensive training in biomedical research design at the UC Berkeley School of Public Health and at the National Institutes of Health places me in a unique position to translate advances in the lab to the bedside.

Moreover, I have broadened my skill set in clinical investigation by completing the Scholars in Clinical Science Program, a two year structured training curriculum that led to a Master of Medical Sciences from Harvard Medical School. I also completed a clinical fellowship in Oncology through the Dana-Farber / Partners Cancer Care Program.

This breadth of clinical training exposed me to the day to day quandaries across the spectrum of solid and hematological tumors. Previously, I was involved with nanotechnology research at the National Cancer Institute where I truly first appreciated the meaning of interdisciplinary.

I continue the spirit of this approach as Director of the Cancer Program within the Massachusetts General Hospital Center for Systems Biology. I am now poised to ask further challenging clinical questions in need of innovative solutions.

My objectives are to refine and translate novel molecular imaging and nanosensing tactics into solid tumors. My efforts have led to inroads into point-of-care diagnostic solutions for resource-constrained regions globally.

My daily research interactions involve an amalgam of chemists, material scientists, engineers, and clinicians as we continue to strive for interdisciplinary, innovative solutions to tackle biological problems plaguing cancer researchers.